Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2020; 8(22): 5564-5575
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5564
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5564
Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
Yang-Yang Ma, Ji-Bing Chen, Central Laboratory, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, Guangdong Province, China
Yin Leng, Yan-Li Xing, Hong-Mei Li, Department of Oncology, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, Guangdong Province, China
Li-Zhi Niu, Department of Interventional Radiology, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, Guangdong Province, China
Author contributions: Ma YY wrote the paper; Leng Y, Xing YL, and Li HM performed the study selection; Chen JB analyzed the data; Niu LZ designed the project and edited the manuscript; all authors reviewed the final manuscript.
Supported by International Science Foundation of Affiliated Fuda Cancer Hospital , Jinan University, No. Y2018-ZD-01 .
Institutional review board statement: The study was reviewed and approved by the Affiliated Fuda Cancer Hospital, Jinan University Institutional Review Board.
Clinical trial registration statement: The study was registered at ClinicalTrials.gov. The registration identification number is NCT02981719.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Li-Zhi Niu, MD, PhD, Chief Physician, Department of Interventional Radiology, Affiliated Fuda Cancer Hospital, Jinan University, No. 2 Tangde West Road, Tianhe District, Guangzhou 510665, Guangdong Province, China. niuboshi@fudahospital.com
Received: August 12, 2020
Peer-review started: August 12, 2020
First decision: August 22, 2020
Revised: August 25, 2020
Accepted: September 26, 2020
Article in press: September 26, 2020
Published online: November 26, 2020
Peer-review started: August 12, 2020
First decision: August 22, 2020
Revised: August 25, 2020
Accepted: September 26, 2020
Article in press: September 26, 2020
Published online: November 26, 2020
Core Tip
Core Tip: Locally advanced pancreatic cancer (LAPC) is a common malignant digestive system tumor with poor prognosis. Gemcitabine (GEM) is currently used as a first-line chemotherapy for treatment of LAPC; however, the overall outcome was poor. Irreversible electroporation (IRE) is a novel, non-thermal ablation technology that uses high voltage electrical pulses to induce pore formation, resulting in cell apoptosis. We found that GEM plus concurrent IRE resulted in significantly prolonging overall survival compared with chemotherapy alone. Therefore, GEM plus concurrent IRE has a synergistic effect on the clinical treatment of LAPC.